QIAGEN

QIAGEN NV is a provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The firm automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D, and industrial applications, primarily forensics). The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

QIAGEN surpasses 2022 targets, eyes growth in diagnostics and biopharma

QIAGEN's strong performance in 2022 exceeded expectations, supported by robust financials and strategic acquisitions.
Despite market challenges, the company remains confident in achieving its 2023 targets, focusing on growth opportunities in diagnostics and biopharma.
Emphasis on innovation, customer knowledge, and strategic shifts position QIAGEN well for sustained growth and leadership in the industry.

QIAGEN surpasses Q1 sales targets, eyes China growth opportunities

QIAGEN's Q1 2023 performance exceeded expectations, with strong sales growth and margin improvements.
The company remains focused on driving growth through product innovation and strategic market expansion.
Challenges include cautious customer spending and evolving market dynamics, particularly in China.
Opportunities lie in capitalizing on strong product performance, investing in new solutions, and expanding market reach.

QIAGEN reports strong Q2 earnings, eyes China growth opportunities

QIAGEN's Q2 performance was solid, driven by key growth areas, but challenges persist with net sales decline and market volatility. The company's strengths in base business sales and focus on growth pillars position it well for future opportunities in China and market expansion.

QIAGEN surpasses Q3 expectations, focuses on sustained growth strategies

QIAGEN's Q3 2023 performance exceeded expectations, showcasing strong financials and strategic leadership changes, with a reaffirmed full-year outlook for 2023.
The company's strengths lie in successful product pillars, sustained growth strategies, and a strategic focus on non-COVID products in key markets.
Challenges include debt repayment impacts, external market uncertainties, and competitive differentiation in expanding product offerings, while opportunities exist in market expansion, innovation, and automation investments.

QIAGEN surpasses Q4 expectations, eyes strategic growth opportunities

QIAGEN's Q4 performance exceeded expectations, showcasing strong growth and profitability.
Challenges include potential risks in Q1 and delays impacting certain product growth.
Strategic investments and upcoming launches present opportunities for continued growth and market expansion.
Overall, QIAGEN's focus on innovation and strategic acquisitions positions them for sustained success in the future.

QIAGEN beats Q1 sales targets, eyes FDA approvals for growth

QIAGEN's Q1 2024 performance exceeded expectations, with strong sales in Diagnostic Solutions. The company reaffirmed its full-year outlook and highlighted advancements in its product portfolio. Despite challenges in the Chinese market, QIAGEN remains focused on growth opportunities and efficient capital allocation.

QIAGEN surpasses Q3 expectations, boosts outlook amid leadership change

QIAGEN delivered strong Q3 results, surpassing expectations and demonstrating improved profitability. Despite leadership changes, the company's strategic initiatives and global positioning bode well for future growth and resilience in the face of market dynamics.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

Qiagen N.V. (QGEN) Q4 2023 Earnings Call Transcript

QIAGEN's (QGEN) fourth-quarter performance reflects impressive CER sales growth and solid profitability.

QIAGEN (QGEN) Q4 Earnings Miss, Operating Margin Expands

Although the revenue and EPS for Qiagen (QGEN) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Qiagen (QGEN) Reports Q4 Earnings: What Key Metrics Have to Say

Q4 2023: Net sales of $509 million (+2% actual rates, +1% constant exchange rates, CER); diluted EPS of $0.42 and adjusted diluted EPS of $0.55 ($0.55 CER vs. $0.53 CER outlook) // FY 2023: Achieved outlook for at least $1.97 billion CER sales and at least $2.07 CER adj. EPS, +8% CER sales growth in non-COVID portfolio and 27% adj. operating income margin // 2024 outlook for at least $2.0 billion CER net sales; adj. diluted EPS of at least $2.10 CER, reflects adj. operating income margin gains but significant non-operating income pressure Q4 2023: Net sales of $509 million (+2% actual rates, +1% constant exchange rates, CER); diluted EPS of $0.42 and adjusted diluted EPS of $0.55 ($0.55 CER vs. $0.53 CER outlook) // FY 2023: Achieved outlook for at least $1.97 billion CER sales and at least $2.07 CER adj. EPS, +8% CER sales growth in non-COVID portfolio and 27% adj. operating income margin // 2024 outlook for at least $2.0 billion CER net sales; adj. diluted EPS of at least $2.10 CER, reflects adj. operating income margin gains but significant non-operating income pressure

QIAGEN exceeds outlook for Q4 2023, led by 8% CER sales growth in non-COVID products and improved operational profitability

QIAGEN (QGEN) announces a first-in-kind collaboration with Penn State University to help shape research, education and outreach in microbiomes.

QIAGEN (QGEN) Forges Alliance to Advance Microbiome Sciences

Partnership aims to help shape research, education and outreach in microbiomes – the community of microorganisms within an environment // QIAGEN to provide instruments and solutions for shared research and education facility at the Huck Institutes' “One Health Microbiome Center” to support faculty and students // Facility at the prominent U.S. university to provide a site for supporting the development of new QIAGEN microbiome solutions Partnership aims to help shape research, education and outreach in microbiomes – the community of microorganisms within an environment // QIAGEN to provide instruments and solutions for shared research and education facility at the Huck Institutes' “One Health Microbiome Center” to support faculty and students // Facility at the prominent U.S. university to provide a site for supporting the development of new QIAGEN microbiome solutions

QIAGEN announces partnership with Penn State University to advance microbiome sciences

Venlo, the Netherlands, Jan. 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced details for completion of the synthetic share repurchase plan to return up to approximately $300 million that combines a direct capital repayment to QIAGEN shareholders with a reverse stock split.

QIAGEN announces details for completion of synthetic share repurchase of up to approximately $300 million

QIAGEN (QGEN) receives FDA clearance for the NeuMoDx CT/NG Assay for use on both NeuMoDx 96 and 288 versions of the integrated PCR-based clinical molecular testing system.

QIAGEN (QGEN) Wins FDA Clearance for NeuMoDx CT/NG Assay

Venlo, The Netherlands, Jan. 11, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the fourth quarter and full year 2023.

QIAGEN N.V. to release results for Q4 2023 and hold webcast

QIAGEN (QGEN) is progressing well with its testing menu expansion strategy, which is driving the company's growth.

QIAGEN (QGEN) Gains From New Alliances Amid FX Headwind

NeuMoDx CT/NG Assay designed to improve accessibility, affordability and timeliness in sexually transmitted infection (STI) testing in the U.S. // U.S. regulatory clearance of new assay for use on both NeuMoDx 96 and 288 versions of integrated PCR-based clinical molecular testing system // Global presence anchored by 16 EU-certified in-vitro diagnostics (CE-IVD) tests, positioning NeuMoDx as having one of the broadest test menus available to customers NeuMoDx CT/NG Assay designed to improve accessibility, affordability and timeliness in sexually transmitted infection (STI) testing in the U.S. // U.S. regulatory clearance of new assay for use on both NeuMoDx 96 and 288 versions of integrated PCR-based clinical molecular testing system // Global presence anchored by 16 EU-certified in-vitro diagnostics (CE-IVD) tests, positioning NeuMoDx as having one of the broadest test menus available to customers

QIAGEN receives FDA clearance of NeuMoDx CT/NG Assay for use on both NeuMoDx 96 and 288 Molecular Systems

Capital return to be conducted through synthetic share repurchase // Return of up to $300 million – maximum approved by shareholders in 2023 – designed to enable efficient return of cash to shareholders and enhance EPS // Implementation planned to be completed in late January 2024 Capital return to be conducted through synthetic share repurchase // Return of up to $300 million – maximum approved by shareholders in 2023 – designed to enable efficient return of cash to shareholders and enhance EPS // Implementation planned to be completed in late January 2024

QIAGEN announces plans to return approximately $300 million to shareholders

Investments into QDI to strengthen No. 1 industry position through profitable expansion into new geographic regions, market segments and enhanced product offerings // QDI offers best-in-class insights for research and clinical customers performing molecular testing and analysis with access to new Omics knowledge bases and improved AI capabilities // Portfolio improvements seek to alleviate informatics bottlenecks for precision medicine and precision care insights Investments into QDI to strengthen No. 1 industry position through profitable expansion into new geographic regions, market segments and enhanced product offerings // QDI offers best-in-class insights for research and clinical customers performing molecular testing and analysis with access to new Omics knowledge bases and improved AI capabilities // Portfolio improvements seek to alleviate informatics bottlenecks for precision medicine and precision care insights

QIAGEN to accelerate investments into QIAGEN Digital Insights bioinformatics business

QIAGEN to open regional headquarters in Riyadh, Saudi Arabia, at the beginning of 2024 to support growing presence in the region // QIAGEN signed Memorandum of Understanding with the Ministry of Health of Saudi Arabia to support public health initiatives // QIAGEN to support Oman's nationwide tuberculosis screening program for expatriates with hundreds of thousands of QuantiFERON-TB Gold Plus tests QIAGEN to open regional headquarters in Riyadh, Saudi Arabia, at the beginning of 2024 to support growing presence in the region // QIAGEN signed Memorandum of Understanding with the Ministry of Health of Saudi Arabia to support public health initiatives // QIAGEN to support Oman's nationwide tuberculosis screening program for expatriates with hundreds of thousands of QuantiFERON-TB Gold Plus tests

QIAGEN expands business in Middle East with new regional headquarters and major projects

Investors remain optimistic about QIAGEN (QGEN), backed by strategic alliances and potential in the Molecular Diagnostics arena.

Here's Why You Should Retain QIAGEN (QGEN) Stock for Now

QIAGEN (QGEN) aims to expand the NGS platform by rapidly scaling up the new Enterprise Genomics Services.

QIAGEN's (QGEN) Strategic Alliances Aid Amid Macro Woes

QIAGEN's ForenSeq Kintelligence System recently used by DNA Labs International in the U.S. to solve unidentified remains case in Oregon and 51-year-old criminal investigation in Georgia // ForenSeq Kintelligence enables identification of distant relatives in genealogy databases, helping to resolve previously unsolvable cases and bringing answers to victims and families // DNA Labs International is one of the first labs to offer this new approach to human identification QIAGEN's ForenSeq Kintelligence System recently used by DNA Labs International in the U.S. to solve unidentified remains case in Oregon and 51-year-old criminal investigation in Georgia // ForenSeq Kintelligence enables identification of distant relatives in genealogy databases, helping to resolve previously unsolvable cases and bringing answers to victims and families // DNA Labs International is one of the first labs to offer this new approach to human identification

DNA Labs International solves significant cold cases with QIAGEN workflow for forensic genetic genealogy

Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock?

Qiagen (QGEN) Up 9.9% Since Last Earnings Report: Can It Continue?

QIAGEN's (QGEN) latest launches will better address the special needs of researchers working with challenging samples, allowing them to work more efficiently.

QIAGEN (QGEN) Expands Sample Technologies Line With New Launch

TissueLyser III bead mill instrument can be used to effectively disrupt samples such as bones, as well as animal and plant tissue to enable access to nucleic acids // TissueLyser III enhances QIAGEN portfolio for high-throughput sample preparation // RNeasy PowerMax Soil Pro Kit compatible with TissueLyser III, utilizes advanced Inhibitor Removal Technology for challenging soil samples as part of a streamlined workflow TissueLyser III bead mill instrument can be used to effectively disrupt samples such as bones, as well as animal and plant tissue to enable access to nucleic acids // TissueLyser III enhances QIAGEN portfolio for high-throughput sample preparation // RNeasy PowerMax Soil Pro Kit compatible with TissueLyser III, utilizes advanced Inhibitor Removal Technology for challenging soil samples as part of a streamlined workflow

QIAGEN launches TissueLyser III and RNeasy PowerMax Soil Pro Kit for improved sample processing and RNA isolation

QIAGEN's (QGEN) new QIAcuity kits are likely to expand application areas and foster digital PCR adoption.

QIAGEN (QGEN) Launches QIAcuity Kits and Software Update

Three new QIAcuity kits enhance digital PCR applications in biopharma research and food safety, ensuring precise quantification, increased sensitivity and cost-efficiency // QIAcuity Software 2.5 update streamlines digital PCR analysis with precise run temperature and sample dilution information, critical to biotech and pharma reporting and auditing // Pipeline of new kits planned to expand application areas and foster digital PCR adoption Three new QIAcuity kits enhance digital PCR applications in biopharma research and food safety, ensuring precise quantification, increased sensitivity and cost-efficiency // QIAcuity Software 2.5 update streamlines digital PCR analysis with precise run temperature and sample dilution information, critical to biotech and pharma reporting and auditing // Pipeline of new kits planned to expand application areas and foster digital PCR adoption

QIAGEN launches new QIAcuity digital PCR kits and updated software to expand use by biopharma and food safety customers

QIAGEN (QGEN) expands the Microbiome solutions portfolio with the launch of Microbiome WGS SeqSets.

QIAGEN (QGEN) Launches Workflow to Boost Microbiome Research

Simplified and accelerated research workflow including high-quality DNA extraction kits, library preparation for whole genome metagenomics, and user-friendly bioinformatics analysis // Workflow enables diverse microbiome research applications, including gut health, soil microbiology, and antibiotic resistance, maximizing DNA diversity and minimizing bias // Expanding growing portfolio of QIAGEN microbiome solutions, covering every aspect of the scientific workflow Simplified and accelerated research workflow including high-quality DNA extraction kits, library preparation for whole genome metagenomics, and user-friendly bioinformatics analysis // Workflow enables diverse microbiome research applications, including gut health, soil microbiology, and antibiotic resistance, maximizing DNA diversity and minimizing bias // Expanding growing portfolio of QIAGEN microbiome solutions, covering every aspect of the scientific workflow

QIAGEN launches complete Sample to Insight workflow for microbiome research

QIAGEN (QGEN) continues to see a very healthy conversion trend from the tuberculin skin test.

News for QIAGEN Stock (QGEN)